Vistagen receives $1.5M from Fuji Pharma for exclusive PH80 negotiation in Japan

Vistagen Therapeutics, Inc.

Received $1.5M non-refundable payment from Fuji Pharma for exclusive negotiation rights to license PH80 in Japan.
PH80 is a non-systemic, hormone-free pherine nasal spray for acute treatment of moderate-to-severe hot flashes due to menopause.
Purchase price credited against signing fee if definitive license agreement reached.
Neither party obligated to enter definitive agreement; negotiations may be terminated after exclusive period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.